Concomitant occurrence of acneiform eruption, alopecia areata, and urticaria during adalimumab treatment in a patient with pustulosis palmoplantaris: Case report and literature review

Adalimumab is a fully human immunoglobulin G1 monoclonal antibody against tumor necrosis factor (TNF)-α that is increasingly used for the treatment of many autoimmune diseases. However, it has also been reported that adalimumab can induce many adverse cutaneous reactions, including paradoxical psori...

Full description

Bibliographic Details
Main Authors: Guan-Yi He, Tsen-Fang Tsai
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2012-06-01
Series:Dermatologica Sinica
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1027811711000899
id doaj-83b6b90418af49ed9a9aae3d5a685525
record_format Article
spelling doaj-83b6b90418af49ed9a9aae3d5a6855252020-11-25T02:32:46ZengWolters Kluwer Medknow PublicationsDermatologica Sinica1027-81172012-06-01302515610.1016/j.dsi.2011.09.010Concomitant occurrence of acneiform eruption, alopecia areata, and urticaria during adalimumab treatment in a patient with pustulosis palmoplantaris: Case report and literature reviewGuan-Yi HeTsen-Fang TsaiAdalimumab is a fully human immunoglobulin G1 monoclonal antibody against tumor necrosis factor (TNF)-α that is increasingly used for the treatment of many autoimmune diseases. However, it has also been reported that adalimumab can induce many adverse cutaneous reactions, including paradoxical psoriasiform eruptions. We describe a patient with pustulosis palmoplantaris who developed four cutaneous adverse reactions, including eczematous lesions, acneiform eruption, alopecia areata, and urticaria during adalimumab treatment. A common histopathological finding in these acneiform and urticarial lesions was the presence of eosinophilic infiltrates. Some authors assume that cross-regulation between TNF-α and interferon-α may contribute to development of a clinical spectrum of cutaneous reactions in predisposed individuals undergoing anti-TNF therapy. The use of different biologics, including adalimumab, etanercept, and ustekinumab, did not seem to improve pustulosis palmoplantaris disease activity in our patient.http://www.sciencedirect.com/science/article/pii/S1027811711000899acneadalimumabalopecia areataurticariaustekinumab
collection DOAJ
language English
format Article
sources DOAJ
author Guan-Yi He
Tsen-Fang Tsai
spellingShingle Guan-Yi He
Tsen-Fang Tsai
Concomitant occurrence of acneiform eruption, alopecia areata, and urticaria during adalimumab treatment in a patient with pustulosis palmoplantaris: Case report and literature review
Dermatologica Sinica
acne
adalimumab
alopecia areata
urticaria
ustekinumab
author_facet Guan-Yi He
Tsen-Fang Tsai
author_sort Guan-Yi He
title Concomitant occurrence of acneiform eruption, alopecia areata, and urticaria during adalimumab treatment in a patient with pustulosis palmoplantaris: Case report and literature review
title_short Concomitant occurrence of acneiform eruption, alopecia areata, and urticaria during adalimumab treatment in a patient with pustulosis palmoplantaris: Case report and literature review
title_full Concomitant occurrence of acneiform eruption, alopecia areata, and urticaria during adalimumab treatment in a patient with pustulosis palmoplantaris: Case report and literature review
title_fullStr Concomitant occurrence of acneiform eruption, alopecia areata, and urticaria during adalimumab treatment in a patient with pustulosis palmoplantaris: Case report and literature review
title_full_unstemmed Concomitant occurrence of acneiform eruption, alopecia areata, and urticaria during adalimumab treatment in a patient with pustulosis palmoplantaris: Case report and literature review
title_sort concomitant occurrence of acneiform eruption, alopecia areata, and urticaria during adalimumab treatment in a patient with pustulosis palmoplantaris: case report and literature review
publisher Wolters Kluwer Medknow Publications
series Dermatologica Sinica
issn 1027-8117
publishDate 2012-06-01
description Adalimumab is a fully human immunoglobulin G1 monoclonal antibody against tumor necrosis factor (TNF)-α that is increasingly used for the treatment of many autoimmune diseases. However, it has also been reported that adalimumab can induce many adverse cutaneous reactions, including paradoxical psoriasiform eruptions. We describe a patient with pustulosis palmoplantaris who developed four cutaneous adverse reactions, including eczematous lesions, acneiform eruption, alopecia areata, and urticaria during adalimumab treatment. A common histopathological finding in these acneiform and urticarial lesions was the presence of eosinophilic infiltrates. Some authors assume that cross-regulation between TNF-α and interferon-α may contribute to development of a clinical spectrum of cutaneous reactions in predisposed individuals undergoing anti-TNF therapy. The use of different biologics, including adalimumab, etanercept, and ustekinumab, did not seem to improve pustulosis palmoplantaris disease activity in our patient.
topic acne
adalimumab
alopecia areata
urticaria
ustekinumab
url http://www.sciencedirect.com/science/article/pii/S1027811711000899
work_keys_str_mv AT guanyihe concomitantoccurrenceofacneiformeruptionalopeciaareataandurticariaduringadalimumabtreatmentinapatientwithpustulosispalmoplantariscasereportandliteraturereview
AT tsenfangtsai concomitantoccurrenceofacneiformeruptionalopeciaareataandurticariaduringadalimumabtreatmentinapatientwithpustulosispalmoplantariscasereportandliteraturereview
_version_ 1724817904033071104